The Food and Drug Administration has rejected deramiocel, a cell therapy developed by Capricor Therapeutics for patients with Duchenne muscular dystrophy. The decision, announced Friday, keeps the treatment off the U.S. market and represents a significant regulatory setback for a company seeking approval in one of the most difficult areas of rare-disease drug development.
Deramiocel had been aimed at teenagers and young men with Duchenne who had already lost the ability to walk, a group with limited therapeutic alternatives and a high risk of progressive complications. Duchenne muscular dystrophy is a genetic, muscle-wasting disorder that primarily affects boys and leads over time to severe weakness, loss of mobility and damage to cardiac and respiratory muscles. For non-ambulatory patients, preserving arm function and slowing heart deterioration are central clinical goals.
Capricor tested deramiocel in two randomized clinical trials. Both studies failed to show that the therapy could prevent or meaningfully delay heart failure, and neither demonstrated that it could preserve muscle function in the arms. Those outcomes left regulators at the Food and Drug Administration without the type of evidence normally needed to support approval, even in a disease where the need for new treatments remains acute.
The rejection also underscores the continuing tension in Duchenne drug regulation. Families, clinicians and companies have pressed for faster access to therapies for a progressive disease with few options, while the agency must determine whether a product’s benefits are established enough to justify market authorization. The field has repeatedly tested the boundaries of evidence standards, particularly when trials involve small patient populations and endpoints that are difficult to measure over short periods.
For Capricor Therapeutics, the FDA decision narrows the immediate path for deramiocel and places renewed attention on whether additional data could address the agency’s concerns. For patients and physicians, it leaves an important unmet medical need unchanged: treatments capable of slowing the later stages of Duchenne, when mobility has already been lost and cardiac decline becomes an increasingly urgent threat.
